Treatment emergent affective switch with topiramate

Tamada, Renata Sayuri; Amaral, Jose Antonio de Mello Siqueira; Issler, Cilly Kluger; Lafer, Beny.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 28(2): 158-158, jun. 2006.
Artículo en Inglés | LILACS | ID: lil-430295

Documentos relacionados

  1. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
  2. Four key questions on the new wave of anti-obesity drugs.
  3. Anti-obesity drugs' side effects: what we know so far.
  4. The discovery of the natural compound Boeravinone-C as a potential antiobesity drug candidate targeting pancreatic lipase using chemo-informatics-based approaches.
  5. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
  6. Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
  7. Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter.
  8. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
  9. Phentermine/topiramate for the treatment of obesity.
  10. Obesity.